Cost–benefit comparison of liraglutide and sitagliptin in the treatment of type 2 diabetes in Thailand

AIM: Liraglutide, a once-daily subcutaneous glucagon-like peptide-1 (GLP-1) agonist, is approved for treatment of hyperglycemia in patients with type 2 diabetes mellitus (T2DM). For patients with established cardiovascular diseases, liraglutide has also been shown to reduce major cardiovascular even...

Descripción completa

Detalles Bibliográficos
Autores principales: Deerochanawong, Chaicharn, Kosachunhanun, Natapong, Gadekar, Arvind V, Chotikanokrat, Pitthaporn, Permsuwan, Unchalee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6635895/
https://www.ncbi.nlm.nih.gov/pubmed/31372015
http://dx.doi.org/10.2147/CEOR.S201951

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6635895/
https://www.ncbi.nlm.nih.gov/pubmed/31372015
http://dx.doi.org/10.2147/CEOR.S201951

Ejemplares similares